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Isavuconazonium sulfate (Cresemba; Astellas Pharma Inc.), a water-soluble prodrug of the triazole antifungal agent isavucona-
zole, is available for the treatment of invasive aspergillosis (IA) and invasive mucormycosis. A population pharmacokinetic
(PPK) model was constructed using nonparametric estimation to compare the pharmacokinetic (PK) behaviors of isavuconazole
in patients treated in the phase 3 VITAL open-label clinical trial, which evaluated the efficacy and safety of the drug for treatment
of renally impaired IA patients and patients with invasive fungal disease (IFD) caused by emerging molds, yeasts, and dimorphic
fungi. Covariates examined were bodymass index (BMI), weight, race, impact of estimated glomerular filtration rate (eGFR) on
clearance (CL), and impact of weight on volume. PK parameters were compared based on IFD type and other patient characteris-
tics. Simulations were performed to describe the MICs covered by the clinical dosing regimen. Concentrations (n 458) from
136 patients were used to construct a 2-compartment model (first-order absorption compartment and central compartment).
Weight-related covariates affected clearance, but eGFR did not. PK parameters and intersubject variability of CL were similar
across different IFD groups and populations. Target attainment analyses demonstrated that the clinical dosing regimen would
be sufficient for total drug area under the concentration-time curve (AUC)/MIC targets ranging from 50.5 for Aspergillus spp.
(up to the CLSI MIC of 0.5 mg/liter) to 270 and 5,053 for Candida albicans (up to MICs of 0.125 and 0.004 mg/liter, respectively)
and 312 for non-albicans Candida spp. (up to a MIC of 0.125 mg/liter). The estimations for Candida spp. were exploratory con-
sidering that no patients with Candida infections were included in the current analyses. (The VITAL trial is registered at
ClinicalTrials.gov under number NCT00634049.)
Isavuconazonium sulfate is the water-soluble prodrug of thenovel, broad-spectrum, triazole antifungal agent isavuconazole
and is available in cyclodextrin-free intravenous (i.v.) and oral
(p.o.) formulations (1). The U.S. Food and Drug Administration
and the European Medicines Agency recently approved isavu-
conazole for the treatment of invasive aspergillosis (IA) and inva-
sive mucormycosis (IM). The approval in the European Union for
mucormycosis is for patients for whom amphotericin B is inap-
propriate. Many of the pharmacokinetic (PK) analyses reported to
date are limited to healthy volunteers and patients treated for IA.
There is a paucity of data regarding the population pharmacoki-
netics (PPK) in patients with a variety of invasive fungal infections
and underlying diseases.
In vitro data for isavuconazole have demonstrated broad-spec-
trum activity against a variety of fungi, including Aspergillus spp.,
Candida spp., Mucorales, Cryptococcus spp., and dimorphic and
other rare fungi (2). In vivo models have also been conducted,
demonstrating concentration-dependent antifungal activity for
the treatment of invasive pulmonary aspergillosis, disseminated
aspergillosis, disseminated candidiasis, mucormycosis, and cryp-
tococcal meningitis (3–7). The VITAL clinical trial evaluated the
efficacy and safety of isavuconazole for treatment of a variety of
invasive fungal diseases (IFD), including the treatment of IA in
patients with renal impairment and treatment of patients with
diseases caused by emerging molds, yeasts, and dimorphic fungi.
Isavuconazole demonstrated successful outcomes for patients
with IA and IM, with all-cause mortality rates through day 42 of
12.5% and 37.8%, respectively, for these patients. Successful out-
comes have also been reported for patients with IA and renal im-
pairment and for patients with infections caused by Cryptococcus
spp., dimorphic fungi (such as Coccidioides spp. and Paracoccid-
ioides spp.), Fusarium spp., and Scedosporium spp. (8–15).
A previous PPK analysis was conducted using isavuconazole
concentration-time data collected from nine phase 1 PK studies of
healthy subjects and the phase 3 SECURE trial of patients with IA
(16). These analyses demonstrated that a 3-compartment model
fit the data well (absorption, central, and peripheral compart-
ments). The PK profiles were similar between healthy subjects and
patients with IA. In addition, isavuconazole demonstrated linear
PK over the range of dosages (40 to 400 mg) that were examined.
An understanding of the PK of novel compounds in various
patient populations is a first critical step for optimal clinical use.
The phase 3 VITAL trial provides the opportunity to compare PK
characteristics for a population of patients infected with a variety
of fungal pathogens. This is especially important for critically ill or
severely immunosuppressed patients and in circumstances where
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organ function is compromised. In the current analysis, we con-
structed a PPK model for patients enrolled in the phase 3 VITAL
trial, with the goal of comparing PK across the different patient
populations to further understand the optimal use of isavucona-
zole.
MATERIALS AND METHODS
Study design. The VITAL trial (ClinicalTrials.gov registration number
NCT00634049) evaluated the efficacy and safety of isavuconazole for the
primary treatment of proven or probable IA in patients with renal impair-
ment and for treatment of patients with proven or probable IFD caused by
Mucorales and other emerging molds, yeasts, and dimorphic fungi. Pa-
tients were eligible whether they required primary therapy or were refrac-
tory or intolerant to their previous systemic antifungal therapy. Patients
received a loading regimen of either i.v. or p.o. isavuconazonium sulfate at
a dose of 372 mg (equivalent to 200 mg isavuconazole) every 8 h for the
first 48 h, followed by i.v. or p.o. isavuconazonium sulfate at 372 mg once
daily for up to a maximum of 180 days. The institutional review board at
each center approved the study protocol, and all research subjects pro-
vided written informed consent.
Plasma PK sampling. Blood samples were collected from each patient
on treatment days 7, 14, and 42 and at the end of therapy. Collection was
targeted at the time point 24 h after the start of the infusion or the p.o. dose
the previous day (i.e., trough concentration). Full 24-h profiles were ob-
tained for a subset of 33 patients. After collection, samples were processed
immediately and stored at 80°C until shipment to the central research
laboratory.
Bioanalytical analysis. Isavuconazole (BAL4815) and inactive cleav-
age product (BAL8728) concentrations in plasma samples were measured
using a validated liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method at Pharmaceutical Product Development, LLC (Middle-
ton, WI). A plasma sample volume of 50 l was combined with the inter-
nal standard (d4-isavuconazole/pyridooxazinone) and subjected to
protein precipitation using acetonitrile. Following centrifugation for 10
min at 5°C, 75 l of the supernatant was isolated for dilution with water:
formic acid:ammonium hydroxide (1,000:10:0.5 [vol/vol/vol])-acetoni-
trile (850:150 [vol/vol]) and then submitted for analysis. Chromato-
graphic separation was achieved using a Synergi Polar-RP column (20
mm by 2.0 mm by 4 m; Phenomenex, Torrance, CA) with a gradient
mobile phase consisting of water, acetonitrile, methanol, and formic acid.
An API3000 mass spectrometer (AB Sciex, Framingham, MA) in positive
ion mode was used to monitor the analytes. Multiple-reaction monitoring
transitions were m/z 438.1¡ 224.1 for isavuconazole, 165.0¡ 121.2 for
the inactive cleavage product, 442.1 ¡ 224.1 for d4-isavuconazole, and
151.1¡ 123.2 for pyridooxazinone. The validated curve range was 5 to
1,250 ng/ml for both isavuconazole and the inactive cleavage product, and
any samples measuring above the upper limit were diluted 5-fold, 10-fold,
or 20-fold prior to analysis. The lower limit of quantification (LOQ) was 5
ng/ml. Interassay precisions (coefficients of variation [%]) of the
BAL4815 quality control samples (12.5, 25, 75, 250, and 1,000 ng/ml) were
6.1%, 4.6%, 3.1%, 2.5%, and 2.6%, respectively, while the interassay ac-
curacies (relative errors [%]) were 2.4%, 3.6%, 3.1%, 2.3%, and 0.2%,
respectively. Interassay precisions of the BAL8728 quality control samples
(12.5, 25, 75, 250, and 1,000 ng/ml) were 7.0%, 7.1%, 5.9%, 8.5%, and
6.5%, respectively, while the interassay accuracies were 1.9%, 0.4%,
1.0%, 2.1%, and 2.8%, respectively. All study samples were analyzed
within the established long-term stability of the drug (isavuconazole)
(955 days at 70°C). All PPK analyses were conducted on the isavu-
conazole concentrations due to the lack of antifungal activity of the
cleavage product.
PPK modeling. A PPK model was developed using nonparametric
estimation in Pmetrics software (v1.3.2; University of Southern Califor-
nia, Los Angeles, CA) (17). The model-fitting process included evalua-
tions of both 2- and 3-compartment models, including absorptive com-
partments with and without a lag time. Data were weighted by the inverse
of the estimated assay variance. Acceptance of the final model was evalu-
ated by visual inspection of the observed versus predicted concentration
values before and after the Bayesian step, the coefficient of determination
(r2) from the linear regression of the observed versus predicted values, and
estimates for bias (mean weighted error) and precision (adjusted mean
weighted squared error).
The impacts of body mass index (BMI), weight, and race (Asian versus
other) on clearance and of weight on volume were initially assessed as
covariates by visual inspection of the graphical representation of each
covariate versus clearance and volume to evaluate for inclusion in the final
model. The covariates were chosen based on results of previous PPK stud-
ies with isavuconazole (16). In addition, this study permitted the enroll-
ment of patients with renal impairment, in contrast to the phase 3
SECURE trial. Therefore, the impact of the estimated glomerular filtra-
tion rate (eGFR) on clearance was also evaluated. The eGFR was calcu-
lated using the serum creatinine level and the “modification of diet in
renal disease” formula.
The average area under the concentration-time curve (AUCavg) for
each patient was calculated using the Bayesian posterior parameter esti-
mates from the final model by using the trapezoidal rule in Pmetrics.
AUCavg was calculated by determining the total AUC over the entire dos-
ing period and dividing it by the number of days of therapy for each
patient. The patients were subclassified according to the type of IFD diag-
nosed at baseline and baseline underlying disease. The PK parameters for
the patient subsets were evaluated separately and compared with the over-
all data set and with those from the previously reported PPK model with
isavuconazole (16). Statistical comparisons were performed in MYSTAT
12 (version 12.02; Systat Software, Inc.).
Simulations of 5,000 patients were performed in Pmetrics to assess the
TABLE 1 VITAL patient demographics and clinical characteristics
Patient population (n)
No. of patients
Body wt (kg)a BMI (kg/m2)aWhite Asian Black Other
Overall (136) 100 23 9 4 70.2 19.5 24.4 5.9
Patients with infection
IA (20) 18 2 0 0 68.0 20.7 23.2 4.7
IM (34) 23 8 3 0 73.4 18.6 25.3 5.5
Other filamentous fungi and molds (23) 17 4 2 0 72.8 25.0 25.1 7.1
Dimorphic fungi (29) 20 4 2 3 64.2 16.1 23.0 5.8
Non-Candida yeasts (10) 5 3 1 1 61.9 11.7 22.2 3.3
Mixed infection (13) 11 1 1 0 75.0 18.7 26.1 7.5
Patients with no pathogen identified (7) 6 1 0 0 79.2 20.4 27.7 5.6
a Data are means SD.
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probability of target attainment (PTA) for the approved clinical dosing
regimen to achieve the various total drug AUC/MIC pharmacodynamic
(PD) targets estimated from preclinical models for different organisms
(i.e., Aspergillus fumigatus, Candida albicans, Candida glabrata, and Can-
dida tropicalis) (5, 18, 19). The choice to use total drug AUC/MIC targets
was considered acceptable because protein binding values are similar be-
tween humans and the animal models used to estimate the targets.
RESULTS
In total, 458 isavuconazole concentrations from 136 patients were
included in the model. Table 1 summarizes the key patient demo-
graphics and clinical characteristics. The majority of the patients
were white. The mean ( standard deviation [SD]) weight and
BMI were 70.2  19.5 kg and 24.4  5.9 kg/m2, respectively.
Fifty-three patients (39%) had an eGFR of60 ml/min/1.73 m2 at
baseline, and the mean eGFR for the total population was 80.2
ml/min/1.73 m2. A total of 65 patients (48%) had one or more of
the following: hematologic malignancy, active malignancy, or
baseline neutropenia. Forty-one percent (n  56) of the overall
population had hematologic malignancies, and 30% (n 41) had
active malignancy at enrollment. One-fourth (n 34) of patients
were neutropenic (absolute neutrophil count [ANC] values of500/
mm3) at baseline. Twenty-four of the 65 patients with hematologic
malignancies had all three baseline characteristics combined, 13
patients were described as having active hematologic malignancies
at baseline, and 5 had both hematologic malignancies and baseline
neutropenia. Fourteen were reported as having only hematologic
malignancies, 4 had only active malignancies, and 5 had only neu-
tropenia. Seventy-one patients did not have any of the three char-
acteristics reported at baseline. Further, 17% of patients had re-
ceived an allogeneic hematopoietic stem cell transplant, and the
use of T-cell immunosuppressants and corticosteroids was re-
ported for 41% and 24% of the overall population, respectively. In
addition to IM (n  34) and IA (n  20), the analysis included
patients with IFD caused by other fungal pathogens, as summa-
rized in Table 1. After IM, the next most commonly enrolled IFD
were caused by dimorphic fungi, such as Coccidioides spp., Para-
coccidioides spp., and Histoplasma spp.
A 2-compartment model with first-order absorption fit the
data well. Figure 1 shows a schematic of the structural model.
Compartment 1 represents the absorptive compartment (i.e.,
gut), and compartment 2 represents the central compartment.
The fit of the PPK model was acceptable based on visual inspection
of the observed versus predicted plots and the coefficient of deter-
mination (r2) of 0.89 for the observed versus posterior predicted
values after the Bayesian step (Fig. 2). The estimates of bias and
precision were also acceptable (0.0539 and 2.77, respectively).
Evaluation of a 3-compartment model did not result in a better fit
of the model to the data.
There was not a statistically significant impact of eGFR or
Asian ethnicity on clearance (Fig. 3A and 4). However, for BMI
and weight, the 95% confidence interval (CI) of the slope did not
include zero, suggesting statistical significance (Fig. 3B and C).
Weight was found to have a significant impact on the volume of
the central compartment (r2 and slope were 0.06 and 2.36 [95%
CI, 0.69 to 4.02], respectively) (Fig. 3D). These covariates were
then incorporated into the structural model to determine if
their inclusion helped to better describe interpatient variabil-
ity. Only one size-related covariate (weight) was included,
Nbolus (1)
RATEIV (1)
V
CL/V
Ka
F
Tlag
1 2
FIG 1 Illustration of the structural model, where compartment 1 represents
the gut for oral administration and compartment 2 represents the central
compartment. CL, clearance; F, bioavailability; Ka, first-order absorption rate
constant; Tlag, lag time; V, volume in the central compartment.
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FIG 2 Observed versus posterior predicted concentrations (milligrams per liter) from the final model after the Bayesian step (r2 0.89; slope 1.05 [95% CI,
1.01 to 1.08]; intercept0.0484 [95% CI,0.179 to 0.0825]). The dotted line is the line of unity where observed concentrations equal predicted concentra-
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since other measures, such as BMI, are less practical measures
in clinical settings. Inclusion of the covariates did not improve
fitting, as assessed by minimal changes in 2 log likelihood
(decrease of 3 points) and Akaike’s information criterion (in-
crease of 5 points) as well as by visual comparisons of the ob-
served versus predicted concentration-time plots for each pa-
tient. Therefore, the base model was used for further evaluation
of model performance.
The mean ( SD) parameter estimates for the overall popula-
tion and classified according to IFD type are shown in Table 2. The
mean clearance for the entire population was 2.5  1.6 liters/h,
and the mean AUCavg was 87.1  41.0 mg · h/liter. The mean
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FIG3 Linear regression plots charting the impacts of eGFR on clearance (A), BMI on clearance (B), weight on clearance (C), and weight on volume in the central
compartment (D). (A) Linear regression for eGFR (r2 and slope were 0.02 and 0 [95% CI, 0 to 0.01], respectively) versus clearance did not find a correlation. (B)
There was a significant relationship between BMI and clearance (r2 and slope were 0.06 and 0.07 [95% CI, 0.02 to 0.11], respectively). (C) There was a significant
relationship between weight and clearance (r2 and slope were 0.06 and 0.02 [95% CI, 0.01 to 0.03], respectively). (D) Linear regression showed a significant
correlation between weight and volume (r2 and slope were 0.06 and 2.36 [95% CI, 0.69 to 4.02], respectively).
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FIG 4 Impact of Asian race on clearance. Box plots for the clearance values for Asian patients (n  23) (median  1.59 liters/h) and other patients (i.e.,
non-Asian; includes white, black or African-American, and “other”; n 113) (median 1.84 liters/h) did not show a statistically significant difference (P 0.06;
Mann-Whitney U test).
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values for clearance and AUCavg ranged from 2.0 to 3.2 liters/h and
70.4 to 94.0 mg · h/liter, respectively, for the individual IFD types.
The intersubject variability of clearance was 63% overall. AUCavg
and clearance values across the different types of IFD were similar
(P 0.420 and 0.248, respectively; Kruskal-Wallis nonparametric
test). The mean estimate for bioavailability was 96.6% for the
overall population (median, 98.2%).
A further review of the PK characteristics was also explored
across the different underlying diseases (Table 3). Clearance val-
ues were comparable for patients with hematologic malignancies,
active malignancies, or baseline neutropenia and patients without
these conditions (P  0.530; Kruskal-Wallis one-way analysis of
variance). The mean clearance and AUCavg values for patients
with hematologic malignancies were 2.8 liters/h and 85.1 mg ·
h/liter, respectively. Patients with a combination of hematologic
malignancy, baseline neutropenia, and active malignancy also had
similar values (2.8 liters/h and 85.1 mg · h/liter for clearance and
AUCavg, respectively). Bioavailability did not vary significantly
across the different underlying disease groups. The intersubject
variability of clearance was consistent across the underlying dis-
ease groups and similar to the overall population value, with val-
ues ranging from 59% to 62%.
The total drug AUC/MIC ratio is the PK-PD index that appears
to best link isavuconazole exposure with efficacy in preclinical
models (18, 19), and PD targets have been defined for both Asper-
gillus spp. and Candida spp. in a range of preclinical models (5, 18,
19). Steady-state AUCs (at day 21) for 5,000 simulated subjects
were assessed over a range of MICs to determine the ability of the
clinical dosing regimen to achieve the various PD targets as a func-
tion of the known MIC distribution. For Aspergillus spp., the PD
target estimated by Seyedmousavi and colleagues (18) for A. fu-
migatus was a total drug AUC/MIC value of 50.5. For Candida
spp., Lepak and colleagues (19) established targets in neutropenic
mice for C. albicans (total drug AUC/MIC  5,053) and non-
albicans Candida spp. (total drug AUC/MIC  312). Figure 5
shows the MIC coverage for each PD target for the isavuconazo-
nium sulfate clinical dosing regimen. Depending on the species,
the clinical dosing regimen would be predicted to adequately
cover Clinical and Laboratory Standards Institute MIC values of
0.5 mg/liter or lower for A. fumigatus and 0.004 and 0.125 mg/liter
or lower for C. albicans and non-albicans Candida spp., respec-
tively. The same analysis was conducted using PD targets from an
additional PK-PD model that was reported for isavuconazole and
C. albicans (5). In this model, PD target values of 270 and 670 were
estimated depending on the extent of neutropenia (temporary
and persistent, respectively). If these total drug AUC/MIC targets
are used for PTA analysis, the results demonstrate that the clinical
dosing regimen will achieve the target for the majority of the C.
albicans MIC distribution (up to MICs of 0.125 and 0.06 mg/liter,
respectively), which has a MIC90 of 0.06 mg/liter.
DISCUSSION
Nonparametric estimation was used to establish a PPK model for
isavuconazole by using Pmetrics and plasma drug concentrations
collected from phase 3 clinical trial patients being treated for a
variety of IFD. A 2-compartment model including an absorptive
compartment with first-order absorption fit the data well. Evalu-
ation of the impact of covariates on clearance revealed a statisti-
cally significant relationship with BMI and weight but no relation-
ship between either eGFR or Asian race and clearance. Weight also
TABLE 2 Isavuconazole PPK parameters in the VITAL study, based on infectiona
Patient population (n) CL (liters/h) (mean SD) V (liters) (mean SD) AUCavg (mg · h/liter) (mean SD) %CV of CL F (%)
Overall (136) 2.5 1.6 361.2 166.3 87.1 41.0 63 96.6
Patients with infection
IA (with renal impairment) (20) 2.3 1.5 412.2 222.4 92.0 44.0 64 97.4
IM (34) 3.0 2.0 364.1 186.0 87.7 56.9 68 95.0
Other filamentous fungi and molds (23) 2.2 0.9 344.2 99.7 80.6 29.2 41 96.9
Dimorphic fungi (29) 2.0 1.3 343.0 159.6 94.0 36.7 62 97.5
Non-Candida yeasts (10) 2.5 1.4 318.2 160.8 92.0 29.5 55 94.9
Mixed infection (13) 3.2 2.0 389.8 162.7 70.4 24.0 62 97.7
Patients with no pathogen identified (7) 2.3 1.6 340.4 107.5 87.8 29.1 68.7 98.2
a CL, clearance; V, volume in the central compartment; %CV, percent covariance of intersubject variability; F, bioavailability.
TABLE 3 Isavuconazole PPK parameters in the VITAL study, based on underlying diseasea
Underlying disease (n)b
CL (liters/h)
(mean SD)
V (liters)
(mean SD)
AUCavg (mg · h/liter)
(mean SD)
%CV
of CL F (%)
Overall (136) 2.5 1.6 361.2 166.3 87.1 41.0 63 96.6
Hematologic malignancy (56) 2.6 1.6 378.7 171.0 85.1 50.2 60 96.2
Active (at baseline) malignancy (41) 2.6 1.6 382.2 165.3 84.4 54.0 59 95.9
Baseline neutropenia (34) 2.7 1.8 406.3 168.0 82.8 57.9 59 96.0
Combined hematologic malignancy, active (at baseline)
malignancy, and baseline neutropenia (24)
2.8 1.8 391.7 187.2 85.1 68.0 62 94.7
Nonec (71) 2.8 1.8 391.8 187.2 85.1 68.0 62 94.7
a CL, clearance; V, volume in the central compartment; %CV, percent covariance of intersubject variability; F, bioavailability.
b Patients in each category are not mutually exclusive.
c Patients without hematologic malignancy, active (at baseline) malignancy, or baseline neutropenia.
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had a significant relationship with the volume of the central com-
partment. However, inclusion of the covariates in the structural
model did not improve the fit of the model to the data. This is
likely due to a weak relationship compared to the relatively large
unexplained PK variability. The overall population parameters
did not differ greatly for the individual IFD types or across the
underlying diseases evaluated, even for severely immunocompro-
mised patients.
We further assessed the adequacy of currently approved regi-
mens by conducting PTA analyses using PD targets defined from
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FIG 5 PTA (left y axes) for PD targets estimated in PK-PD animal models for the common fungal pathogens A. fumigatus (A), non-albicans Candida (B), and
C. albicans (C). Each graph illustrates the proportion of 5,000 simulated subjects achieving each of the PD targets at each MIC value after administration of the
clinical dosing regimen of isavuconazonium sulfate. Isavuconazole CLSI MIC distributions (right y axes) are provided for A. fumigatus (n 855) (A), C. glabrata
(n 254) and C. tropicalis (n 130) (B), and C. albicans (n 844) (C).
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experimental models for specific fungal pathogens. The results
were consistent with previous data reported for Aspergillus spp.
(16). For Candida spp., this represents the first report of a PTA
analysis conducted using the PD targets for Candida spp. Impor-
tantly, however, this study did not include patients with invasive
candidiasis. The majority of such cases occur in the context of
critical illness, where the PK may be reasonably different and have
an impact upon both the PD and PTA. Further analyses must be
performed to characterize any differences in PK for patients with
invasive candidiasis and then to determine if these differences
have any impact on the exposure coverage of the MIC distribution
for these organisms. The isavuconazole MIC50 and MIC90 for C.
albicans were 0.002 and 0.06 mg/liter, respectively, for a collection
of 844 isolates (20–32). For the non-albicans Candida spp. tested
in the PK-PD model of disseminated candidiasis, the isavucona-
zole MIC50 and MIC90 were 0.03 and 1 mg/liter, respectively, for
C. tropicalis (n 130) and 0.06 and 1 mg/liter, respectively, for C.
glabrata (n  254) (20–32). If no differences in the PK of isavu-
conazole exist for patients with candidemia or invasive candidiasis
and the patients described herein, the current analysis suggests
that the clinical dosing regimen will achieve the PD target reported
by Lepak and colleagues (19) for the majority of the non-albicans
Candida spp. but not for C. albicans. However, a second model
which evaluated the PD target for C. albicans was also explored
and gave different results (5). These total drug AUC/MIC targets
demonstrated that the clinical dosing regimen would achieve the
target for the majority of the C. albicans MIC distribution (up to
MICs of 0.125 and 0.06 mg/liter). For other important fungi, such
as organisms of the Mucorales order, Cryptococcus spp., and di-
morphic fungi, validated in vivo PK-PD models have not been
fully established. This demonstrates a clear knowledge gap for
optimizing therapy for life-threatening infections with these or-
ganisms.
A previous PPK model was conducted for isavuconazole by
using parametric estimation in NONMEN 7.2 software (16), us-
ing plasma concentration data from nine trials involving healthy
subjects and one large phase 3 clinical trial of patients with IA or
infections with other filamentous fungi (SECURE trial). Desai et
al. (16) employed a Weibull absorption function and did not es-
timate the lag time and bioavailability. In our analysis, a 2-com-
partment model with an absorptive compartment was better than
a 3-compartment model with an absorptive compartment as
previously described by Desai et al. This is likely due to sparse
sampling for the large majority of patients. Regardless of the
differences between the two structural models, the mean clear-
ance values estimated from both models are similar (2.5 liters/h
versus 2.4 liters/h). Important patient characteristics that po-
tentially have an impact on drug exposure were also explored.
We did not identify differences in the heterogeneous popula-
tion based on IFD type or underlying diseases. The intersubject
variability of clearance was consistent among the populations,
even for the severely immunocompromised (i.e., patients with
hematologic malignancy, active malignancy, and neutropenia
combined at baseline).
We did not find a statistically significant relationship between
race and clearance, in contrast to a previous report by Desai et al.
that race (Asian) is associated with reduced clearance (16). The
relationship between race and clearance in the current data may
not have been seen because of the differences in sample size. The
current analysis included 23 Asian patients, whereas the study of
Desai et al. included 53 Asian patients. Desai et al. suggested that
the influence of race-dependent CYPs on clearance is likely to be
minimal because isavuconazole is not a substrate of CYP2D6 or
CYP2C19 isoenzymes (16). However, additional pharmacoge-
netic studies are required to further elucidate the potential im-
pacts of race on clearance and drug exposure. Desai et al. did not
report a relationship for weight and clearance but did find a rela-
tionship between BMI and volume. Both race and weight impacts
on clearance and weight impacts on volume were included in the
final model. While we identified significant covariates, inclusion
of the covariates in the structural model did not significantly
change the model fit to the data. The reasons for this could be that
the size of the Asian population and range of weights in the data set
were not large enough to significantly affect the model or that the
relationships of these covariates to clearance and volume are not
strong.
We reported the AUCavg for the population by calculating
the total AUC for the dosing duration and dividing it by the
number of days of therapy. It is important that the average
treatment duration of therapy for the population in the PK data
set was only 14 days, compared to the average duration for the
study, which was 135 days. Therefore, the values for AUCavg
reported here are slightly lower than they would be if we were
reporting steady-state AUC. The population mean estimate of
AUCavg was 87.1 mg · h/liter, and the mean steady-state AUC
for the 5,000 simulated patients was 94.4 mg · h/liter. This was
comparable to the mean estimates obtained for each of the
individual IFD types and to that obtained for the patients from
the SECURE trial (16).
Isavuconazole clearance and AUC were not different across
the various IFD and underlying diseases from the VITAL trial
and were similar to the reported clearance and AUC values for
patients with IA in the SECURE analyses (16). The values for
intersubject variability of clearance across the populations,
even for the small group of patients with severe immunosup-
pression, and between the VITAL and SECURE studies were
similar, further illustrating the predictability of the PK of isa-
vuconazole in most patients. For comparison, the reported in-
tersubject variability of AUC for posaconazole ranges from 62
to 80%, and that for voriconazole ranges from 120 to 168%,
depending on the formulation administered and the patient
population studied (33, 34).
PTA analysis offers an estimate of the coverage of MIC values
provided by the clinical dosing regimen for common fungal
pathogens. The results suggest that for the most common patho-
gens for which PD targets have been estimated, the clinical dosing
regimen provides adequate coverage of the majority of the wild-
type MIC distribution for A. fumigatus, Aspergillus flavus, and
Aspergillus terreus strains, and the results support previous PTA
analyses (16) for these organisms. For C. albicans and non-albi-
cans Candida species, the results suggest reasonable coverage of
the isavuconazole MIC distribution from a large collection of in
vitro susceptibility studies. However, further analyses are neces-
sary to characterize the PK characteristics for patients infected
with invasive candidiasis and candidemia. This is especially im-
portant given that a recently completed phase 3 clinical trial of the
treatment of candidemia did not meet the primary endpoint of
overall response at the end of intravenous isavuconazole therapy
compared to caspofungin therapy (35). If there are PK differences
in critically ill patients treated for candidemia and invasive candi-
Kovanda et al.
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diasis, this may affect the outcome of the clinical breakpoint se-
lection, and potentially the recommended dosing regimen for
treatment of invasive candidiasis.
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